Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment

被引:9
|
作者
Fokkema, E
de Vries, EGE
Groen, HJM
Meijer, C
Timens, W
机构
[1] Univ Groningen Hosp, Dept Pathol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Pulm Dis, NL-9700 RB Groningen, Netherlands
[3] Univ Groningen Hosp, Dept Med Oncol, NL-9700 RB Groningen, Netherlands
关键词
apoptosis; small cell lung cancer; rat; platinum resistance;
D O I
10.1007/s00428-003-0763-9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Purpose: In order to understand the apoptosis pathway in tumor cells, differences in cell morphology and expression of apoptosis-related proteins induced by radiation and/or chemotherapy, were investigated in a rat double tumor model comparing cisplatin-sensitive and-resistant human small cell lung cancer tumors. Methods: The cisplatin-sensitive human small cell lung cancer cell line (GLC4) and its cisplatin-resistant subline (GLC4-CDDP) were each injected subcutaneously in a different hind limb of the rat. After 15-17 days, radiation (10 Gy), carboplatin (25 mg/ka, intraperitoneal), combined treatment, or no treatment was administered. In combined treatment, carboplatin was administered 24 h before radiation. Tumors were removed and fixed 72 h after carboplatin or 48 h after radiation. Paraffin-embedded slides were stained with hematoxylin/eosin for morphology. Expression of the apoptosis-related proteins p53, p21. Rb. bcl-2, bax, c-myc, Fas and Fas-L was assessed immunohistochemically. Results: In the GLC4 tumor, carboplatin treatment increased tumor cell size, tumor cell size heterogeneity, and number of apoptotic tumor cells. After radiation and combined treatment, these changes were more pronounced and multinuclear giant cells were observed. In GLC4-CDDP tumors, minimal changes were detected after carboplatin. Following radiation slight increases in tumor cell size, tumor cell size heterogeneity and number of apoptotic tumor cells were observed. No multinuclear giant cells were seen. After combined treatment, GLC4-CDDP showed cellular changes comparable to those in GLC4 cells after radiation or combined treatment, but no giant cells were observed. Untreated, both tumors were equally positive for p53, bax, Fas, FasL, c-myc and negative for Rb. Contrary to GLC4, untreated GLC4-CDDP tumors showed no p21 and bcl-2 expression. After combined treatment, an increase in number of bcl-2 positive cells was found in GLC4-CDDP tumors. No p21 was induced in GLC4-CDDP by any treatment modality. In GLC4 tumors, p21 was induced by radiation alone. No further changes in protein expression were induced by any treatment in GLC4 tumors. Conclusion: Following therapy, morphological changes in cell size and cell size heterogeneity were more pronounced in GLC4 than in GLC4-CDDP tumors. However, morphological changes in GLC4-CCDP tumors after treatment indicate that carboplatin plus radiotherapy may be effective also in cisplatin resistant tumor cells. An increase in p21 in GLC4 after radiation might facilitate apoptosis. The increase in number of Bcl-2 positive cells after combined treatment and the consistently negative p21 status after any treatment in GLC4-CDDP may protect these tumor cells from apoptosis as a part of their resistance mechanism to cisplatin.
引用
收藏
页码:349 / 355
页数:7
相关论文
共 50 条
  • [31] Elemene injection combined with radiotherapy in treatment for non-small cell lung cancer with brain metastasis
    Hou, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Secondary Hodgkin Lymphoma and MDS after Paclitaxel-Carboplatin Treatment in a Patient with Small Cell Lung Cancer
    Petrushevska, Marija
    Stavrdis, Irina Panovska
    Petrusevska, Gordana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S322 - S323
  • [33] WEEKLY DIVIDED CARBOPLATIN COMBINED WITH IRINOTECAN IN PATIENTS WITH SMALL-CELL LUNG CANCER AS THE FIRST-LINE TREATMENT
    Son, C.
    Roh, M. S.
    Um, S. J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S80 - S80
  • [34] Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer
    Ajzensztejn, D
    Hegde, VS
    Lee, SM
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2389 - 2391
  • [35] Radiolabelled antibody combined with external radiotherapy (RACER) for the treatment of non-small cell lung cancer (NSCLC).
    Epenetos, A
    ANNALS OF ONCOLOGY, 2000, 11 : 121 - 121
  • [36] Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer
    Mueller, J. A.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S117 - S118
  • [38] Association between Treatment-related Pneumonitis and the Overall Survival after Definitive Radiotherapy for Non-small Cell Lung Cancer
    Yuan, X.
    Tucker, S.
    Komaki, R.
    Martel, M.
    Zhuang, Y.
    Cox, J.
    Milas, L.
    Mohan, R.
    Liao, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S473 - S473
  • [39] Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment
    Kong, Cheng
    Yu, Shaorong
    Qian, Pudong
    Song, Xue
    Wen, Jing
    Jiang, Ming
    Zhu, Jun
    Xu, Jianhua
    Zhao, Lijun
    Guo, Zhen
    Wu, Jianfeng
    He, Xia
    Zhu, Xiangzhi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer
    Goto, Yasushi
    Sekine, Ikuo
    Tanioka, Maki
    Shibata, Takashi
    Tanai, Chiharu
    Asahina, Hajime
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Kunitoh, Hideo
    Ohe, Yuichiro
    Kikkawa, Hironori
    Ohki, Emiko
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1548 - 1556